Global Benralizumab Drug Market Size: Analysis by Indication (Asthma, Eosinophilic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Respiratory Disorders), By Dosage Form (Prefilled Syringes, Auto-injectors, Other Injectable Forms), By End-User (Hospitals, Specialty Clinics, Homecare Settings): Global and Regional Demand Supply Trends and Forecast-2026-2033.

Market Outlook

The Benralizumab Drug Market was valued at USD 1,689 Million in 2024 and is projected to grow to USD 2,976 Million by 2030, with a compound annual growth rate (CAGR) of 10.06% from 2025 to 2030. The Global Benralizumab Drug Market plays an essential role in the pharmaceutical industry, primarily due to its effectiveness in treating severe eosinophilic asthma and other related conditions. Benralizumab, known by its brand name Fasenra from AstraZeneca, is a monoclonal antibody that targets IL-5 receptors on eosinophils. This innovative approach helps to reduce asthma flare-ups and enhances lung function for those affected.
 

History

Benralizumab, known by its brand name Fasenra, is a biologic injection used for patients suffering from severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis who do not get enough relief from standard treatments. Patients typically receive this medication every four weeks for the first three doses, and then it is administered every eight weeks afterward. This schedule helps reduce asthma flare-ups and improve lung function. 

Some common side effects include headaches and throat irritation, but there is also a risk of rare yet serious allergic reactions. It’s important to note that Fasenra is not meant for treating sudden asthma attacks. In the U.S., the drug is protected by regulatory exclusivity until 2029, with major patents expected to stay in effect until around 2030 to 2034. This situation may delay the introduction of biosimilars, although the specifics can vary by country depending on local patent laws and extensions.

In July 2015, AstraZeneca entered an exclusive option agreement with Kyowa Hakko Kirin for the potential commercialisation of benralizumab in Japan for asthma and chronic obstructive pulmonary disease (COPD). Benralizumab, a humanised monoclonal antibody targeting the interleukin-5 receptor (IL-5Rα) to deplete eosinophils, was in Phase III clinical development for severe uncontrolled asthma and COPD at that time. Under the agreement, AstraZeneca paid a $45 million upfront option fee with additional regulatory, approval, milestone, and royalty payments due upon progress. Kyowa Hakko Kirin retained development responsibilities in Japan, while AstraZeneca secured rights to assume sales and marketing if the option was exercised. Before this partnership, Kyowa Hakko Kirin held exclusive rights in Japan and parts of Asia, and AstraZeneca held rights elsewhere, including the US and Europe. The arrangement aimed to expand benralizumab’s availability and introduce an innovative therapy for patients with severe respiratory disease in Japan.

Key Insights

North America accounted for the largest share of the Benralizumab Drug market at 62.11% in 2024. North America is the leading region for the Benralizumab drug market, primarily because asthma and eosinophilic diseases are quite common here. The healthcare infrastructure is well-developed, making it easier for patients to access treatments. In the United States, Benralizumab (known as Fasenra) is widely used. This is largely due to high healthcare spending, advanced ways to diagnose conditions, and supportive reimbursement policies that make it easier for patients to get the medication they need. 

Key players like AstraZeneca play a significant role in this market, alongside strong regulatory support, which together help boost growth. As more patients and healthcare providers learn about the benefits of targeted biologic therapies, awareness and demand for these treatments continue to rise. Canada also adds to this trend with its growing healthcare system, although on a smaller scale compared to the U.S., further solidifying North America's prominent position in this market.

In terms of Indication, the Eosinophilic Asthma accounted for a major share of 32.1% in 2023. Eosinophilic asthma is a key player in the global market for the drug benralizumab. This medication, known as Fasenra and developed by AstraZeneca, has a unique way of working that makes it particularly effective for this type of asthma. It specifically targets interleukin-5 receptors (IL-5R) found on eosinophils, which are a type of white blood cell involved in the inflammation and flare-ups of severe eosinophilic asthma. By binding to these receptors, benralizumab helps to quickly reduce the levels of eosinophils in the body.

Because of its proven effectiveness and the fact that it’s widely approved and recommended as a supplemental treatment for severe eosinophilic asthma, benralizumab has taken a leading position in the market. While it can also be used for other conditions like chronic obstructive pulmonary disease (COPD), its impact there is not as significant due to fewer approvals and lower usage rates.

Clinical Trials  

Market Dynamics

Increasing cases of severe asthma and COPD globally have fueled the demand for biologic treatments like benralizumab, which specifically targets eosinophilic inflammation.
 

The rising number of cases of severe asthma and Chronic Obstructive Pulmonary Disease (COPD) around the world has led to a growing interest in advanced biologic treatments, such as benralizumab. This medication is particularly effective because it targets eosinophils, a type of white blood cell that plays a key role in the inflammation associated with these conditions. 
For many patients suffering from severe asthma or COPD, especially those whose symptoms are driven by eosinophils, benralizumab presents a promising option where traditional treatments may have fallen short.

Asthma affects millions of people globally, and for those with elevated eosinophil levels, the disease can become particularly severe. Benralizumab offers a fresh approach by binding to the IL-5 receptor on eosinophils, leading to their depletion. This process helps decrease inflammation in the airways, which can reduce the frequency of asthma attacks and improve lung function for those who have struggled to find effective relief.

COPD a chronic respiratory condition marked by persistent inflammation, can also involve heightened eosinophilic activity in certain patients. Benralizumab's targeted mechanism provides substantial benefits for individuals with eosinophilic COPD, helping to decrease exacerbations and enhance overall quality of life.

The high cost of biologic therapies, including benralizumab, can limit access for patients in low- and middle-income countries.
 

The high cost of biologic therapies like benralizumab creates a major barrier for patients in low- and middle-income countries (LMICs). These biologics are inherently more expensive than traditional medications due to the complicated manufacturing processes and the extensive research and regulatory requirements that come with them. As a result, benralizumab is often priced at a level that is simply out of reach for many individuals in LMICs, where healthcare budgets are tight and out-of-pocket expenses can be overwhelming.

In these areas, the challenge is compounded by a lack of strong healthcare insurance systems and insufficient government support for these costly treatments. Although biologics can provide significant benefits for patients dealing with severe asthma and COPD, their high prices often lead to situations where treatment is rationed or completely unavailable, ultimately worsening health outcomes. This situation underscores the urgent need for innovative pricing strategies, subsidies, or global initiatives aimed at making these life-saving therapies accessible to those who need them the most in underserved communities.

Segmental Analysis

Based on Indication, Benralizumab Drug market is segmented into Asthma, Eosinophilic Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Other Respiratory Disorders.

 
The Eosinophilic Asthma segment is set to lead the global market for Benralizumab due to the rising rates of eosinophilic asthma and a deeper understanding of its underlying mechanisms. This specific type of asthma is noted for having high levels of eosinophils white blood cells that play a significant role in airway inflammation. Benralizumab, which is an anti-IL-5 monoclonal antibody, has shown impressive results in targeting and reducing these eosinophils, helping to improve asthma control and decrease the frequency of flare-ups.

As more patients are being diagnosed with eosinophilic asthma, particularly those with severe and uncontrolled cases, the demand for Benralizumab is on the rise. This medication has become a crucial option for individuals whose asthma isn’t sufficiently managed by standard treatments like inhaled corticosteroids. With ongoing clinical studies demonstrating Benralizumab's effectiveness in reducing asthma attacks, hospital visits, and the need for oral corticosteroids, it’s increasingly favored by both patients and healthcare professionals.

The segment is benefiting from the advancements in personalized medicine. Benralizumab works especially well for patients who have high eosinophil levels, allowing for more customized and effective treatment strategies. The growing recognition and acceptance of biologic therapies for severe asthma are further driving the market, making the eosinophilic asthma segment a major factor in the overall growth of the Benralizumab market.

Regional Landscape

In the context of regional analysis, the Benralizumab Drug market includes North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

The market size of the North America was valued at USD 1,049 Million in 2024 and is expected to reach USD 1,848 Million by 2030, with a CAGR of 9.71% during the forecast period. North America is leading the way in the Benralizumab drug market, largely due to the high number of people dealing with asthma and chronic obstructive pulmonary disease (COPD). This high prevalence creates a strong demand for effective treatments. The United States is a key player in this market, holding the largest share. 

Several factors explain why North America is at the forefront. For one, both the U.S. and Canada have a significant number of patients suffering from asthma and COPD, particularly those with severe eosinophilic asthma, the condition that Benralizumab specifically targets. The rising number of cases is influenced by issues like pollution, smoking, and changes in the environment, all of which have led to a greater need for advanced biologic treatments.

The approval of Benralizumab by the U.S. Food and Drug Administration (FDA) for severe eosinophilic asthma has also played a crucial role in its widespread acceptance and use. The FDA’s efficient approval process, along with the availability of biologics, has made it easier to access this treatment in the region. Canada has followed suit by also approving the drug, which opens up a larger market.

Another important aspect is the well-established healthcare system in North America, which features robust reimbursement policies. Health insurance in the region typically covers biologic treatments like Benralizumab, making it more accessible for many patients. There’s a strong awareness among healthcare providers and patients about the advantages of biologics, which further fuels the demand for treatments like Benralizumab.

All in all, North America’s combination of high disease prevalence, supportive regulations, and an advanced healthcare infrastructure ensures that it remains a dominant player in the Benralizumab market.

Competitive Landscape 

Some of the major companies operating within the Benralizumab Drug market are: AstraZeneca, Others.